HBCo — Hofseth Biocare ASA Income Statement
0.000.00%
Last trade - 00:00- NOK614.57m
- NOK847.60m
- NOK256.34m
Annual income statement for Hofseth Biocare ASA, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 87.6 | 120 | 195 | 257 | 256 |
| Cost of Revenue | |||||
| Gross Profit | 2.51 | 28.5 | 44.2 | 87.9 | 95.4 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 206 | 249 | 297 | 362 | 369 |
| Operating Profit | -119 | -129 | -103 | -105 | -112 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -126 | -137 | -107 | -125 | -135 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -126 | -137 | -107 | -125 | -135 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -126 | -137 | -107 | -125 | -135 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -126 | -137 | -107 | -125 | -135 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.347 | -0.363 | -0.331 | -0.321 | -0.328 |